1,959 Elevance Health, Inc. $ELV Shares Acquired by Sterling Capital Management LLC

Sterling Capital Management LLC raised its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 3.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,969 shares of the company’s stock after acquiring an additional 1,959 shares during the quarter. Sterling Capital Management LLC’s holdings in Elevance Health were worth $21,373,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Elevance Health in the second quarter worth about $7,344,424,000. Bank of New York Mellon Corp bought a new position in Elevance Health during the 2nd quarter worth approximately $1,246,349,000. Legal & General Group Plc acquired a new position in shares of Elevance Health in the 2nd quarter worth approximately $688,469,000. Amundi increased its holdings in shares of Elevance Health by 145.7% in the 1st quarter. Amundi now owns 2,693,664 shares of the company’s stock valued at $788,570,000 after acquiring an additional 1,597,497 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Elevance Health in the 2nd quarter valued at approximately $591,084,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ELV shares. TD Cowen boosted their price objective on shares of Elevance Health from $465.00 to $495.00 and gave the company a “buy” rating in a research report on Friday. Leerink Partners raised their target price on shares of Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Robert W. Baird upped their target price on Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Royal Bank Of Canada increased their price target on Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a research report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $455.57.

Elevance Health Stock Performance

NYSE ELV traded down $5.23 on Friday, hitting $440.05. The stock had a trading volume of 1,173,816 shares, compared to its average volume of 1,329,873. The company’s 50-day moving average is $408.32 and its two-hundred day moving average is $390.89. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69. The stock has a market cap of $95.43 billion, a price-to-earnings ratio of 18.77, a P/E/G ratio of 2.32 and a beta of 0.70. The company has a quick ratio of 1.52, a current ratio of 1.47 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. During the same quarter in the previous year, the company posted $6.03 earnings per share. The business’s revenue for the quarter was up .7% compared to the same quarter last year. On average, analysts expect that Elevance Health, Inc. will post 27.09 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio is presently 29.34%.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Insider Activity at Elevance Health

In other news, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.34% of the company’s stock.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.